Cutaneous Mastocytosis Treatment Market By Drug Type (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents, Photochemotherapy), By Pipeline Analysis (Phase III, Phase II) - Growth, Future Prospects and Competitive Analysis, 2018-2026

Industry Outlook

The cutaneous mastocytosis treatment market was worth US$ 186.7 million in 2017 and is expected to grow at a 5.6% CAGR from 2018 to 2026. Cutaneous mastocytosis is a rare disease in which uncontrolled production of mast cells leads to skin complications such as lesions, blisters, and rashes with aggravated itching. The key causes of cutaneous mastocytosis are a mutation in the KIT gene, which leads to the overproduction of mast cells, and excess accumulation of mast cells in the skin, which leads to both chronic and acute reactions. The major factors that are driving this market are raising awareness related to the disease among physicians, which is assisting the growth of the prevalence rate and is expected to further assist the growth in research and development of target-specific treatment against cutaneous mastocytosis.

Market Synopsis

Photochemotherapy has satisfactory results, and it is becoming the treatment of choice for most dermatologists in both developed and developing countries.

Photochemotherapy (PUVA) is identified as the fastest-growing segment throughout the forecast period from 2018 to 2026 due to an effective combination of the drug Psoralens and long-wave ultraviolet radiation to treat cutaneous mastocytosis, which is accepted and practiced by several dermatologists from both developed and developing countries. The patients were initially exposed to psoralens, drugs that contain chemicals that react with ultraviolet light and, later, UVA light. However, the number of photochemotherapy sessions required for a patient suffering from cutaneous mastocytosis is in the range of 10 to 15 times a month.

Asia Pacific is the fastest-growing market due to rising awareness among dermatologists about rare skin diseases and developing healthcare infrastructure in developing countries.

During the forecast period from 2018 to 2026, Asia Pacific was identified as the fastest-growing cutaneous mastocytosis treatment market, mainly due to increasing awareness among dermatologists related to rare genetic disorders and developing healthcare infrastructure, which is assisting the diagnosis rate. Significant economic growth in the Asia Pacific developing and developed countries has boosted overall infrastructure development in all sectors, including healthcare, transportation, education, and others. This has led to an increase in opportunities for local as well as migrating individuals due to the fact that the population of Caucasians is also increasing in the Asia Pacific, and as the study suggests, cutaneous mastocytosis is observed mainly in Caucasians.

Periods of History and Forecast

The cutaneous mastocytosis treatment market was examined using current market trends for the base year of 2017, and CAGRs were calculated based on future trends for the forecast period of 2018 to 2026.

Report Scope by Segments

This report covers an exhaustive study of the cutaneous mastocytosis treatment market, including market interpretations and assumptions analyzed based on elaborative qualitative and quantitative data segregated through primary and secondary research. Primary interviews with industry stakeholders aided in the analysis and understanding of market dynamics, such as opportunities, drivers, and challenges, which were further segmented by region and respective countries. This report also covers a complete study of several segments of global cutaneous mastocytosis treatment, such as the type of drug class and geography. Pipeline analysis covers information related to two molecules that are under clinical trial and expecting approval in the near future. The report also provides an understanding of the competitive landscape in which the key companies operate and present in the cutaneous mastocytosis treatment market, which includes company data points such as current and future business strategies, financial data, and product portfolios.

The key companies currently available in the market were analyzed based on recent market updates, product portfolios, financial data, and major strategies. This report also includes an attractive investment proposition analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, and Mallinckrodt Pharmaceuticals, among others.

Key questions are answered in this report.

  • Which drug class is in high demand to treat cutaneous mastocytosis, and why?
  • What are the current market strategies and policies being researched and implemented by major market players, as well as the competitive landscape of the global cutaneous mastocytosis treatment market?
  • Which are the crucial and impending geographical markets (regions and countries) in the cutaneous mastocytosis treatment market, and why?
  • Which is the largest and fastest-growing region globally?
  • What will be the expected sales of drugs under development?

 Frequently Asked Questions:

The market for Cutaneous Mastocytosis Treatment Market is expected to reach At US$ 186.7 Mn in 2026.

The Cutaneous Mastocytosis Treatment Market is expected to see significant CAGR growth over the coming years, at 5.6

The report is forecasted to 2018-2026

The base year of this report is 2017.

Pfizer Inc.,Merck & Co., Inc., EPI Health, LLC.,kaleo, Inc.,Bausch Health Companies Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Apr 2019
Category:  Pharmaceuticals
Report ID:   59649
Report Format:   PDF
Pages:   120
Rating:    4.2 (58)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support